Drug-resistant tuberculosis: an insurmountable epidemic? (Q37815427)

23 August 2017

1 reference

title

Drug-resistant tuberculosis: an insurmountable epidemic? (English)

1 reference

23 August 2017

0 references

1 reference

Amitabha Chakroborty

1

1 reference

23 August 2017

3 December 2010

1 reference

23 August 2017

1 reference

23 August 2017

19

1 reference

23 August 2017

3

1 reference

23 August 2017

131-137

1 reference

https://scigraph.springernature.com/pub.10.1007/s10787-010-0072-2

23 August 2017

0 references

cites work

Timing of initiation of antiretroviral drugs during tuberculosis therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

Rapid molecular detection of tuberculosis and rifampin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

Increasing transparency in partnerships for health--introducing the Green Light Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

Extensively drug-resistant tuberculosis, Italy and Germany

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

21 January 2018

12 December 2020

Comprehensive treatment of extensively drug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

A comparison of outbreak- and nonoutbreak-related multidrug-resistant tuberculosis among human immunodeficiency virus-infected patients in a South African hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10787-010-0072-2

Picking up the pace--scale-up of MDR tuberculosis treatment programs

21 January 2018

1 reference

12 December 2020

Programmes and principles in treatment of multidrug-resistant tuberculosis

1 reference

12 December 2020

Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study

1 reference

12 December 2020

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

1 reference

12 December 2020

Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings.

1 reference

12 December 2020

Extensively drug-resistant tuberculosis in the United States, 1993-2007.

1 reference

12 December 2020

Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.

1 reference

12 December 2020

10.1007/S10787-010-0072-2

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21127999